Giovanna Vinci-Khoury
Psychiatry · Youngstown, OHNPI 1124080239
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,063 and has fallen 94.8% since, to $55 in 2023.
Across 189 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$451
- AbbVie$310
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$282
- Supernus Pharmaceuticals, Inc.$213
- Teva Pharmaceuticals USA, Inc.$185
- Neurocrine Biosciences, Inc.$183
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,80998%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $451 |
| AbbVie(2 entities) | 21 | $310 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $282 |
| Supernus Pharmaceuticals, Inc. | 17 | $213 |
| Teva Pharmaceuticals USA, Inc. | 19 | $185 |
| Neurocrine Biosciences, Inc. | 13 | $183 |
| Lundbeck LLC | 11 | $182 |
| Vanda Pharmaceuticals Inc. | 10 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $153 |
| Shire North American Group Inc | 6 | $93 |
| Vertical Pharmaceuticals, LLC | 5 | $81 |
| Corium, LLC | 4 | $79 |
| Ironshore Pharmaceuticals Inc. | 4 | $72 |
| Tris Pharma Inc | 4 | $69 |
| Johnson & Johnson | 4 | $65 |
| Noven Therapeutics, LLC | 4 | $58 |
| Neos Therapeutics, LP | 3 | $56 |
| Almatica Pharma LLC | 3 | $46 |
| Adlon Therapeutics L.p. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Indivior Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,856 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 12 | $834 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Youngstown
- Unknown AdityanjeeYoungstown$85K
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.